Keywords: s-p, tra, meets, ph, ii, study, endpoints

S-P's TRA meets Ph II study endpoints

Article | 23 March 2009

Print This

US drug major Schering-Plough says that SCH 530348, its novel oral thrombin receptor antagonist, met the primary endpoints of safety and ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in